Commentary Conflicting clinical trial data: a lesson from albuminAssistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care, Emory University School of Medicine, Atlanta, Georgia, USA
Critical Care 2005, 9:649-650doi:10.1186/cc3931
See related research article http://ccforum.com/content/9/6/R745 AbstractAlbumin is a frequently prescribed drug in hospitalized patients, and its effect on clinical outcomes has been scrutinized in recent years. Data from meta-analyses has suggested harm related to albumin therapy in critically ill patients, and new observational data are consistent with these results. However, appropriately powered randomized, controlled trials have shown albumin to be safe in broad groups of critically ill patients. This article will discuss the reasons for differences between observational and controlled trial data, and the implications for future albumin use and clinical research. |




on Google Scholar







author email
corresponding author email